Full-Time

Regional Hematology Manager

Confirmed live in the last 24 hours

Omeros

Omeros

201-500 employees

Develops therapeutics for inflammation and CNS disorders

No salary listed

Senior, Expert

Dallas, TX, USA

Remote

Must reside in assigned territory; overnight and weekend travel is required.

Category
Field Sales
Sales & Account Management
Requirements
  • Bachelor’s degree is required, with a concentration in the life sciences or healthcare field preferred; MBA or an advanced degree is preferred
  • 10 years of sales experience in the pharmaceutical industry, with a minimum of 5 years of rare disease or orphan disease territory management experience; experience in hematology and especially HSCT is also a plus
  • Launch experience is required with a demonstrated track record of success
  • Specialty experience is required, oncology and hematology experience preferred
  • Experience working with major Blood and Marrow Transplant Centers and the key opinion leaders within those centers
Responsibilities
  • Responsible for managing the business within a specific geographical territory area
  • Responsible for disease state awareness materials and educating customers on the signs and symptoms of thrombotic microangiopathy (TMA) as it relates to HSCT patients in their targeted institutions
  • Participate in and help create pre-launch strategies that will be used to ensure a successful launch of a product currently under review by the FDA for the treatment of HSCT-TMA
  • Pending FDA approval, this individual will be responsible for educating customers on a monoclonal antibody used to treat HSCT-TMA in targeted hospitals that are located across the assigned territory with a focus on the following departments: HSCT physicians, hematologists, nephrologists, nurses, and pharmacists
  • Some responsibilities as it relates to the reimbursement and access of the product and will call on Pharmacy directors, social workers and others related to ensuring the access and distribution of the product
  • Execute on the National sales and marketing strategy and create a territory business plan to maximize opportunity
  • Work in partnership with home office personnel, the Brand team and the National and Corporate account teams for pull-through of product sales
  • Responsible for running the business by analyzing account and physician sales data and creating territory tactical plans and providing solutions to grow the business
  • Experience in and knowledge of Microsoft applications as well as Veeva CRM in order to track call activity and sales progress
  • Maintain Company and Industry Compliance Rules
Desired Qualifications
  • Possess in-depth knowledge of the medical industry (Pharmaceutical, Hospital, Specialty Pharmacy, Biologics/Biotech)
  • Familiarity with adding products to Hospital Formularies
  • Knowledge of products used in the HSCT arena (Chemotherapy, radiation, supportive care products) is preferred
  • Documented, consistent, above-average performance in prior sales positions
  • Strong organizational skills and ability to manage multiple tasks/priorities
  • Above average proficiency with basic technology tools (e.g. Microsoft Office products, Veeva CRM, etc.)
  • Demonstrated ability to build and maintain positive relationships with management, peers, and subordinates
  • Integrity

Omeros focuses on creating and selling medicines that treat various health conditions, particularly those related to inflammation, blood clotting issues, and central nervous system disorders. The company develops both small-molecule drugs and protein-based therapies to address these medical needs. Omeros stands out from its competitors by targeting both common diseases and rare conditions, known as orphan indications, which often receive less attention from other pharmaceutical companies. The goal of Omeros is to improve patient outcomes by providing effective treatments for a wide range of health issues.

Company Size

201-500

Company Stage

IPO

Headquarters

Charlottesville, Virginia

Founded

1994

Simplify Jobs

Simplify's Take

What believers are saying

  • Omeros received a $6.7M grant from NIDA for OMS527, boosting addiction treatment research.
  • Wellington Management's $305,000 investment shows confidence in Omeros' pipeline and market potential.
  • Omeros' presentations at major congresses enhance its visibility and scientific credibility.

What critics are saying

  • Omeros' net loss increased to $108.8 million for the nine months ending September 2023.
  • Reliance on grants like the $6.7M from NIDA may pose future funding risks.
  • Success depends on investigational drugs like OMS906 and narsoplimab receiving regulatory approval.

What makes Omeros unique

  • Omeros focuses on developing treatments for complement-mediated diseases and addictive disorders.
  • The company is advancing OMS527 for cocaine use disorder at NIDA's request.
  • Omeros' OMS906 targets the alternative pathway of complement, a unique therapeutic approach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Wire
Mar 13th, 2025
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company's OMS527 Program to Treat Cocaine Use Disorder

Omeros is developing OMS527 for the treatment of CUD at NIDA's direct request.

BioSpace
Feb 17th, 2025
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation announces availability on its website of materials accompanying narsoplimab presentations at the 2025 Tandem Meetings.

MarketBeat
Dec 21st, 2024
Wellington Management Group LLP Makes New $305,000 Investment in Omeros Co. (NASDAQ:OMER)

Wellington Management Group LLP makes new $305,000 investment in Omeros Co. (NASDAQ:OMER).

Bizjournals
Jun 18th, 2024
Omeros names chief accounting officer from within

Seattle-based biopharmaceutical company Omeros Corp. (Nasdaq: OMER) named David Borges as the company's chief accounting officer in a Wednesday regulatory filing.

Business Wire
May 9th, 2024
Omeros Corporation Announces Upcoming Presentations At 2024 European Hematology Association (Eha) Hybrid Congress

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been selected for podium presentation. The EHA Congress will be held June 13-16, 2024, in Madrid, Spain. OMS906 is Omeros’ investigational inhibitor of MASP-3 targeting the alternative pathway of complement. Two additional poster presentations directed to OMS906 will also be featured at the congress.The abstracts for all three presentations are scheduled to be published on May 14, 2024 and will be available on the EHA website at ehaweb.org. Details of the congress presentations are found below.OMS906, A Novel Alternative Pathway MASP-3 Inhibitor, Improved Hematologic Parameters in PNH Patients with Suboptimal Response to Ravulizumab Treatment: Phase 2 Dose-Finding Study Interim Results (Abstract #S189)Session Name: s454 Clinical and translational in bone marrow failure syndromes and PNHDate: Saturday, June 15, 2024Podium Presentation Session Time: 4:30 p.m. CESTLocation: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall N102Presenting Author: Morag Griffin MBChB, FRCPathClinical Pharmacology of OMS906, a Potent Inhibitor of MASP-3 and the Alternative Pathway of Complement Activation (Abstract #P834)Date: Friday, June 14, 2024Presentation Time: 6:00 p.m